Table 1.
Overview of study measures.
| Measure | Domain measured | T0 | I | T1 | T2 |
|---|---|---|---|---|---|
| Primary outcome | |||||
| Motor Activity Log—14 Item Version (MAL—14) (Amount of Use) | Patient-reported amount of upper limb use in daily life | X | X | X | |
| Secondary outcomes | |||||
| MAL—14 (Quality of Movement) | Patient-reported quality of upper limb use in daily life | X | X | X | |
| Fugl-Meyer Assessment—Upper Extremity | Upper limb motor function | X | X | X | |
| Action Research Arm Test | Upper limb capacity | X | X | X | |
| EuroQol Five Dimensions Five Levels Questionnaire | Health-related quality of life | X | X | X | |
| Modified Rankin Scale | Global disability | X | X | X | |
| Global Rating of Perceived Changes | Self-perceived change | X | X | ||
| Quantitative Sensor Data | Compliance; activity counts of the paretic and non-paretic side | X | |||
| Adverse Events | Safety | X | X | X | X |
| Other measures | |||||
| Demographics | Participant demography | X | |||
| Stroke Event Data | Disease characteristics | X | |||
| Charlson Comorbidity Index | Medical history | X | |||
| National Institutes of Health Stroke Scale | Neurological impairments | X | |||
| Edinburgh Handedness Inventory | Handedness | X | |||
| Apples Test | Visuospatial neglect | X | |||
| Concomitant Therapy | Standard rehabilitation therapy | X | X | X | |
I, intervention; T0, baseline; T1, post-intervention; T2, 6-week follow-up.